Dolutegravir treatment around the time of conception is not associated with an increased risk of neural tube defects in infants exposed to the drug at the time of conception, the most recent surveillance report from Botswana’s Tsepamo study has concluded. Indeed, the prevalence of neural tube defects in infants exposed to dolutegravir shows a downward trend compared with earlier surveillance periods, say the investigators.
The findings, presented as a late-breaker poster at the 24th International AIDS Conference (AIDS 2022), confirm study updates provided in 2019 and 2020 and provide further reassurance that women of childbearing potential can receive dolutegravir-based antiretroviral treatment in the same way as other adults and children.
Read the full story at Aidsmap.
For more coverage of AIDS 2022, click here.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.